Comparative Pharmacology
Head-to-head clinical analysis: CABAZITAXEL versus TAXOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CABAZITAXEL versus TAXOL.
CABAZITAXEL vs TAXOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Microtubule inhibitor. Binds to tubulin and promotes microtubule assembly while inhibiting disassembly, leading to mitotic arrest and cell death. Also inhibits tubulin deacetylation and has anti-angiogenic properties.
Paclitaxel stabilizes microtubules by binding to the β-tubulin subunit, preventing depolymerization, thereby disrupting mitotic spindle formation, cell division, and intracellular transport.
25 mg/m2 intravenously every 3 weeks in combination with oral prednisone 10 mg daily.
Intravenous infusion of 175 mg/m² over 3 hours every 3 weeks for ovarian carcinoma; 135 mg/m² over 24 hours every 3 weeks for breast carcinoma; 100 mg/m² over 3 hours every 2 weeks for NSCLC; 175 mg/m² over 3 hours every 2 weeks for AIDS-related Kaposi sarcoma.
None Documented
None Documented
Clinical Note
moderateCabazitaxel + Verteporfin
"The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Verteporfin."
Clinical Note
moderateCabazitaxel + Digoxin
"Cabazitaxel may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBetaxolol + Digoxin
"Betaxolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateCabazitaxel + Digitoxin
"Cabazitaxel may decrease the cardiotoxic activities of Digitoxin."
Terminal half-life approximately 95 h (range 77–120 h) in patients with normal hepatic function; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 5.3 to 16.3 hours (mean ~13 hours); exhibits triphasic elimination with a prolonged terminal phase due to extensive tissue binding.
Primarily hepatobiliary (76% in feces as metabolites), renal (2-3% unchanged; 20% total in urine as metabolites).
Primarily hepatic metabolism via CYP2C8 and CYP3A4; biliary/fecal excretion accounts for ~70% of total clearance; renal excretion is minimal (<10% as unchanged drug).
Category C
Category C
Taxane Antineoplastic
Taxane Antineoplastic